Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open, booster vaccination study to assess safety and reactogenicity of GSK Biologicals' dTpa vaccine (Boostrix) when administered to healthy Chinese children 6-8 years of age

Trial Profile

Open, booster vaccination study to assess safety and reactogenicity of GSK Biologicals' dTpa vaccine (Boostrix) when administered to healthy Chinese children 6-8 years of age

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jan 2007 Status change
    • 11 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top